enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Hepatitis C - Wikipedia

   en.wikipedia.org/wiki/Hepatitis_C

   The initial recommended treatment depends on the type of hepatitis C virus, if the person has received previous hepatitis C treatment, and whether the person has cirrhosis. [88] Direct-acting antivirals are the preferred treatment and have been validated by testing for virus particles in patients' blood.

3. Sofosbuvir - Wikipedia

   en.wikipedia.org/wiki/Sofosbuvir

   Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C. [3] It is taken by mouth. [3] [6]Common side effects include fatigue, headache, nausea, and trouble sleeping. [3]

4. Ledipasvir/sofosbuvir - Wikipedia

   en.wikipedia.org/wiki/Ledipasvir/sofosbuvir

   Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. [8] It is a fixed-dose combination of ledipasvir and sofosbuvir. [8] Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotype 1. [9] Some evidence also supports use in HCV genotype 3 and 4. [9]

5. Here's What Hepatitis C Actually Is—and How You Get It - AOL

   www.aol.com/heres-hepatitis-c-actually-172028789...

   In all cases, after just 12 weeks of treatment, 95 percent of people diagnosed with hepatitis C are cured. How to Prevent Hepatitis C Cured of hepatitis C, however, doesn’t mean immune.

6. List of antiviral drugs - Wikipedia

   en.wikipedia.org/wiki/List_of_antiviral_drugs

   Hepatitis C Sofosbuvir: Hepatitis C [17] nucleoside analogue reverse transcriptase inhibitor: Stavudine: HIV Taribavirin (Viramidine) Hepatitis Syndromes in which Ribavirin is active [18] Telaprevir: Hepatitis C Telbivudine (Tyzeka) Hepatitis B: Tenofovir alafenamide: Hepatitis B: Tenofovir disoproxil: Hepatitis B, HIV [19] Tipranavir: HIV ...

7. Ledipasvir - Wikipedia

   en.wikipedia.org/wiki/Ledipasvir

   Ledipasvir is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. [1] After completing Phase III clinical trials, on February 10, 2014, Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. [2] [3] The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication ...